Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation

scientific article published on 02 June 2009

Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1600-0609.2009.01280.X
P698PubMed publication ID19500138

P50authorMałgorzata Krawczyk-KulisQ125269742
Joanna DziaczkowskaQ125270002
Jerzy HołowieckiQ11724708
Miroslaw MarkiewiczQ60233376
Piotr KuśnierczykQ82758549
Tomasz CzerwQ88230103
Sebastian GiebelQ92489652
Slawomira Kyrcz-KrzemienQ114428269
Aleksandra Hołowiecka-GoralQ114775716
P2093author name stringIzabela Nowak
Jerzy Wojnar
Agnieszka Karolczyk
Malgorzata Kopera
P433issue4
P304page(s)343-356
P577publication date2009-06-02
P1433published inEuropean Journal of HaematologyQ15765799
P1476titleActivating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation
P478volume83

Reverse relations

cites work (P2860)
Q35594106A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation
Q38079585Clinical relevance of natural killer cells following hematopoietic stem cell transplantation
Q64997781Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Q36775731Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors
Q33701536Does the KIR2DS5 gene protect from some human diseases?
Q36061068Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Q37786500Natural killer cells and tumor control
Q41618466Role of killer immunoglobulin-like receptor and ligand matching in donor selection
Q53344984Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT.
Q38478878Therapeutic potential and challenges of natural killer cells in treatment of solid tumors

Search more.